The mechanistic effects of spironalactone in diastolic heart failure

August 27, 2012

Mineralocorticoid receptor antagonists should be considered as a treatment option in hypertensive patients with diastolic heart failure, said Professor Burkert Pieske presenting results today of the Aldosterone Receptor Blockade in Diastolic Heart Failure (Aldo-DHF) study at ESC Congress 2012.

Behind his conclusion lay results showing that mineralocorticoid receptor blockade with spironolactone improves cardiac function and structure, reduces neuroendocrine activation, and effectively reduces blood pressure in a patient population with symptomatic predominantly hypertensive diastolic . However, results also showed that spironolactone did not improve or symptoms of heart failure.

As background to the study Professor Pieske, Head of Cardiology at the Medical University Graz in Austria, explained that diastolic heart failure (DHF) - also known as heart failure with preserved - is a condition which increasingly affects millions of people in Europe. Today, he said, more than half of all have DHF, as opposed to classical , and DHF is the dominant form of heart failure in elderly patients, especially women. Patients suffer from poor quality of life, impaired exercise capacity and a high rate of hospitalisation and mortality.

"Mechanistically," said Professor Pieske, "the main underlying pathology is thought to be impaired filling of the , often as a consequence of long-standing hypertension, diabetes, and other lifestyle-associated cardiovascular risks factors. However, despite the large number of affected patients and the poor outcome, no therapy has so far demonstrated .

"The neuroendocrine hormone aldosterone mediates, through mineralocorticoid receptors, adverse effects on cardiac function and remodelling, as well as on vascular stiffness. In consequence, aldosterone induces myocardial hypertrophy, fibrosis and diastolic dysfunction, all potential mechanistic factors in the pathology of diastolic heart failure. However, despite this mechanistic evidence and convincing benefits in systolic heart failure, aldosterone antagonism has never been tested in a large randomised multicentre trial in patients with DHF."

The Aldo-DHF trial was designed to test the hypothesis that 12 months treatment with the mineralocorticoid receptor antagonist spironolactone would improve and structure, as well as exercise capacity and quality of life in patients with DHF. The study was an international multicentre Phase IIb trial funded after peer review by the German government within the Clinical Trial Research Program.

Aldo-DHF prospectively randomised 422 patients with symptomatic DHF to either spironolactone (target dose, 25 mg/day) or placebo over a treatment period of 12 months. The two co-primary endpoints were changes in diastolic function (filling pressure, assessed non-invasively by tissue-Doppler derived E/é, an established and validated echocardiographic estimate of left ventricular filling pressure) and changes in maximal exercise capacity (peak oxygen consumption, VO2), assessed by bicycle spiroergometry after 12 months.

Secondary endpoints included other parameters of echocardiographic functional and structural cardiac abnormalities, submaximal exercise capacity, quality of life and NYHA class. Safety including classical side effects such as increase in serum potassium or decreases in renal function were also assessed.

Results showed that spironolactone significantly improved diastolic function (assessed as a significant decline in E/é), but did not change maximal exercise capacity (peak V02) after one year. Spironolactone also induced reverse cardiac remodelling and reduced left ventricular hypertrophy, a known detrimental consequence of hypertension and diabetes), NTproBNP plasma levels, and systolic and diastolic blood pressure.

However, spironolactone did not improve other measures of exercise capacity, NYHA class, or quality of life, but was shown to be safe, without relevant adverse events.

Results from the NIH-funded TOPCAT trial will show if these beneficial effects of spironolactone translate into better clinical outcome.

Explore further: A heart-rate-reducing medication reduces the risk of heart failure and cardiac fibrosis

Related Stories

A heart-rate-reducing medication reduces the risk of heart failure and cardiac fibrosis

July 28, 2011
The findings of a Montreal Heart Institute (MHI) study published in the scientific journal Cardiology suggest that ivabradine, a heart rate reduction medication, is also effective in reducing the risk of diastolic heart failure ...

New data from studies bolsters case for using aldosterone antagonists in heart failure

September 19, 2011
Roughly 5 million people in the United States live with heart failure, a condition in which the heart is unable to pump blood around the body effectively. The causes and types of heart failure vary greatly, and treatment ...

Diastolic dysfunction appears to worsen over time; associated with increased risk of heart failure

August 23, 2011
A follow-up of participants in a heart function study finds that the prevalence of left ventricular diastolic dysfunction (left ventricular filling [with blood] is abnormal and is accompanied by elevated filling pressures) ...

Recommended for you

Could aggressive blood pressure treatments lead to kidney damage?

July 18, 2017
Aggressive combination treatments for high blood pressure that are intended to protect the kidneys may actually be damaging the organs, new research from the University of Virginia School of Medicine suggests.

Quantifying effectiveness of treatment for irregular heartbeat

July 17, 2017
In a small proof-of-concept study, researchers at Johns Hopkins report a complex mathematical method to measure electrical communications within the heart can successfully predict the effectiveness of catheter ablation, the ...

Concerns over side effects of statins stopping stroke survivors taking medication

July 17, 2017
Negative media coverage of the side effects associated with taking statins, and patients' own experiences of taking the drugs, are among the reasons cited by stroke survivors and their carers for stopping taking potentially ...

Study discovers anticoagulant drugs are being prescribed against safety advice

July 17, 2017
A study by researchers at the University of Birmingham has shown that GPs are prescribing anticoagulants to patients with an irregular heartbeat against official safety advice.

Protein may protect against heart attack

July 14, 2017
DDK3 could be used as a new therapy to stop the build-up of fatty material inside the arteries

Heart study finds faulty link between biomarkers and clinical outcomes

July 14, 2017
Surrogate endpoints (biomarkers), which are routinely used in clinical research to test new drugs, should not be trusted as the ultimate measure to approve new health interventions in cardiovascular medicine, according to ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.